Список литературы:
Easton D., Pharaoh P., Eccles D. BRCA1 and BRCA2. In: Oxford desk reference. Clinical genetics. Oxford University Press. 2009. P.426-429. Breast Cancer Linkage Consortium. Carrier risks in BRCA 2 mutation carriers. J Natl Cancer Inst 1999; 91: 1310-1316. Antoniou A., Pharoah P., Narod S., et al. Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies. Am J Hum Genet. 2003; 72(5): 1117–1130. Любченко Л.Н., Поспехова Н.И., Шабанов М.И. и др. Влияние герминальных мутаций гена BRCA 1 на фенотипическое проявление рака молочной железы. Тезисы IV Российской Онкологической Конференции Москва 21-23 ноября 2000. c.84-85. Honrado E., Benitez J., Palacios J. The molecular pathology of hereditary breast cancer: genetic testing and therapeutic implications. Modern Pathology. 2005, 18, 1305–1320. Haffty B.G., Harrold E., Khan A.J., et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002;359 (9316):1471-1477. Garcia-Etienne C.A., Barile M., Gentilini O.D., et al. Breast-conserving surgery in BRCA1/2 mutation carriers: are we approaching an answer? Ann Surg Oncol. 2009; 16(12): 3380-3387. Pierce L.J., Phillips K.A., Griffith K.A., et al. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010; 121(2):389-398. Chappuis P.O., Goffin J., Wong N., et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet. 2002; 39(8):608-610. Hubert A., Mali B., Hamburger T., et al. Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer. Fam Cancer. 2009;8(3):173-177. Byrski T., Huzarski T., Dent R., et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009; 115(2):359-363. Byrski T., Gronwald J., Huzarski T., et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2010; 28(3):375-379. Kriege M., Seynaeve C., Meijers-Heijboer H., et al. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2009; 27(23):3764-3771. Brekelmans C.T., Seynaeve C., Menke-Pluymers M., et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol. 2006;17(3):391-400. Любченко Л.Н. Наследственный рак молочной железы и/или яичников: ДНК-диагностика, индивидуальный прогноз, лечение и профилактика. Автореферат дисс. …д.м.н. Москва 2009. 50 с. Jernstrom H., Lerman C., Ghadirian P., et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet, 1999, 354(9193), 1846-1850. Brinton L.A. & Devesa S.S. Incidence, Demographics, and Enviromental Factors. In: Harris J.R., Morrow M., Lippman M.E., et al., eds.: Diseases of the Breast. Lippincott-Raven Publishers: Philadelphia, Pa, 1996, pp 159-168. King M.-C., Wieand S., Hale K., et al. Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2 National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001; 286:2251-2256. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 2005; 97, 22, 1652-1662. Visvanathan K., Chlebowski R.T., Hurley P., et al. American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. J Clin Oncol, 2009, 27, 19, 3235-3258. Vogel V.G., Costantino J.P., Wickerham D. L., et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer Cancer Prev Res 2010; 3(6), 696–706. Rebbeck T.R., Kauff N.D., Domchek S.M. Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers. J Natl Cancer Inst. 2009; 101(2): 80–87. Hartmann L.C., Schaid D.J., Woods J.E. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340(2):77-84. McDonnell S.K., Schaid D.J., Myers J.L., et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol 2001; 19(19):3938-3943. Hartmann L.C., Sellers T.A., Schaid D.J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633-1637. Rebbeck T.R., Friebel T., Lynch H.T. Bilateral Prophylactic Mastectomy Reduces Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group. J Clin Oncol 2004; 22,6:1055-1062.
Еще по теме Список литературы::
- Список рекомендуемой литературы Основная литература
- Список рекомендуемой литературы и веб-сайты
- Список литературы и материалов
- Список литературы
- Список литературы
- Список литературы
- Список литературы
- Список литературы
- Список литературы
- Список литературы.
- Список литературы
- Список литературы
- Список литературы
- Список литературы
- Список литературы
- Список литературы
- Список литературы
- Список литературы: